405 related articles for article (PubMed ID: 26250435)
1. A randomized trial of iron isomaltoside 1000 versus oral iron in non-dialysis-dependent chronic kidney disease patients with anaemia.
Kalra PA; Bhandari S; Saxena S; Agarwal D; Wirtz G; Kletzmayr J; Thomsen LL; Coyne DW
Nephrol Dial Transplant; 2016 Apr; 31(4):646-55. PubMed ID: 26250435
[TBL] [Abstract][Full Text] [Related]
2. A randomized, open-label, non-inferiority study of intravenous iron isomaltoside 1,000 (Monofer) compared with oral iron for treatment of anemia in IBD (PROCEED).
Reinisch W; Staun M; Tandon RK; Altorjay I; Thillainayagam AV; Gratzer C; Nijhawan S; Thomsen LL
Am J Gastroenterol; 2013 Dec; 108(12):1877-88. PubMed ID: 24145678
[TBL] [Abstract][Full Text] [Related]
3. A randomized, open-label trial of iron isomaltoside 1000 (Monofer®) compared with iron sucrose (Venofer®) as maintenance therapy in haemodialysis patients.
Bhandari S; Kalra PA; Kothari J; Ambühl PM; Christensen JH; Essaian AM; Thomsen LL; Macdougall IC; Coyne DW
Nephrol Dial Transplant; 2015 Sep; 30(9):1577-89. PubMed ID: 25925701
[TBL] [Abstract][Full Text] [Related]
4. A Randomized Noninferiority Trial of Intravenous Iron Isomaltoside versus Oral Iron Sulfate in Patients with Nonmyeloid Malignancies and Anemia Receiving Chemotherapy: The PROFOUND Trial.
Birgegård G; Henry D; Glaspy J; Chopra R; Thomsen LL; Auerbach M
Pharmacotherapy; 2016 Apr; 36(4):402-14. PubMed ID: 26927900
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of iron isomaltoside 1000/ferric derisomaltose versus iron sucrose in patients with chronic kidney disease: the FERWON-NEPHRO randomized, open-label, comparative trial.
Bhandari S; Kalra PA; Berkowitz M; Belo D; Thomsen LL; Wolf M
Nephrol Dial Transplant; 2021 Jan; 36(1):111-120. PubMed ID: 32049331
[TBL] [Abstract][Full Text] [Related]
6. NIMO-CKD-UK: a real-world, observational study of iron isomaltoside in patients with iron deficiency anaemia and chronic kidney disease.
Kalra PA; Bhandari S; Spyridon M; Davison R; Lawman S; Mikhail A; Reaich D; Pritchard N; McCafferty K; Moore J
BMC Nephrol; 2020 Dec; 21(1):539. PubMed ID: 33302891
[TBL] [Abstract][Full Text] [Related]
7. Protocol and baseline data for a prospective open-label explorative randomized single-center comparative study to determine the effects of various intravenous iron preparations on markers of oxidative stress and kidney injury in chronic kidney disease (IRON-CKD).
Ziedan A; Bhandari S
Trials; 2019 Apr; 20(1):194. PubMed ID: 30947751
[TBL] [Abstract][Full Text] [Related]
8. Iron isomaltoside 1000: a new intravenous iron for treating iron deficiency in chronic kidney disease.
Wikström B; Bhandari S; Barany P; Kalra PA; Ladefoged S; Wilske J; Thomsen LL
J Nephrol; 2011; 24(5):589-96. PubMed ID: 21240875
[TBL] [Abstract][Full Text] [Related]
9. A prospective observational study of iron isomaltoside in haemodialysis patients with chronic kidney disease treated for iron deficiency (DINO).
Mikhail AI; Schön S; Simon S; Brown C; Hegbrant JBA; Jensen G; Moore J; Lundberg LDI
BMC Nephrol; 2019 Jan; 20(1):13. PubMed ID: 30630452
[TBL] [Abstract][Full Text] [Related]
10. FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia.
Macdougall IC; Bock AH; Carrera F; Eckardt KU; Gaillard C; Van Wyck D; Roubert B; Nolen JG; Roger SD;
Nephrol Dial Transplant; 2014 Nov; 29(11):2075-84. PubMed ID: 24891437
[TBL] [Abstract][Full Text] [Related]
11. The FIND-CKD study--a randomized controlled trial of intravenous iron versus oral iron in non-dialysis chronic kidney disease patients: background and rationale.
Macdougall IC; Bock A; Carrera F; Eckardt KU; Gaillard C; Van Wyck D; Roubert B; Cushway T; Roger SD;
Nephrol Dial Transplant; 2014 Apr; 29(4):843-50. PubMed ID: 24170814
[TBL] [Abstract][Full Text] [Related]
12. Conversion of haemodialysis patients from iron sucrose to iron isomaltoside: a real-world experience.
Jesus-Silva JA; Lamplugh A; Dhada S; Burton JO; Bhandari S
BMC Nephrol; 2020 Jun; 21(1):212. PubMed ID: 32493240
[TBL] [Abstract][Full Text] [Related]
13. Intravenous iron isomaltoside improves hemoglobin concentration and iron stores in female iron-deficient blood donors: a randomized double-blind placebo-controlled clinical trial.
Gybel-Brask M; Seeberg J; Thomsen LL; Johansson PI
Transfusion; 2018 Apr; 58(4):974-981. PubMed ID: 29424441
[TBL] [Abstract][Full Text] [Related]
14. Treatment of iron deficiency in patients with chronic kidney disease: A prospective observational study of iron isomaltoside (NIMO Scandinavia)
.
Jensen G; Gøransson LG; Fernström A; Furuland H; Christensen JH
Clin Nephrol; 2019 Apr; 91(4):246-253. PubMed ID: 30614439
[TBL] [Abstract][Full Text] [Related]
15. Renal function in patients with non-dialysis chronic kidney disease receiving intravenous ferric carboxymaltose: an analysis of the randomized FIND-CKD trial.
Macdougall IC; Bock AH; Carrera F; Eckardt KU; Gaillard C; Van Wyck D; Meier Y; Larroque S; Roger SD;
BMC Nephrol; 2017 Jan; 18(1):24. PubMed ID: 28095881
[TBL] [Abstract][Full Text] [Related]
16. Safety and Efficacy of Intravenous Ferric Derisomaltose Compared to Iron Sucrose for Iron Deficiency Anemia in Patients with Chronic Kidney Disease With and Without Heart Failure.
Ambrosy AP; von Haehling S; Kalra PR; Court E; Bhandari S; McDonagh T; Cleland JGF
Am J Cardiol; 2021 Aug; 152():138-145. PubMed ID: 34162484
[TBL] [Abstract][Full Text] [Related]
17. Intravenous iron isomaltoside 1000 (Monofer®) reduces postoperative anaemia in preoperatively non-anaemic patients undergoing elective or subacute coronary artery bypass graft, valve replacement or a combination thereof: a randomized double-blind placebo-controlled clinical trial (the PROTECT trial).
Johansson PI; Rasmussen AS; Thomsen LL
Vox Sang; 2015 Oct; 109(3):257-66. PubMed ID: 25900643
[TBL] [Abstract][Full Text] [Related]
18. A prospective observational study of effectiveness and safety of iron isomaltoside in patients with chronic renal failure and iron deficiency anemia
.
Biggar P; Leistikow F; Walper A
Clin Nephrol; 2016 Dec; 86 (2016)(12):310-318. PubMed ID: 27737531
[TBL] [Abstract][Full Text] [Related]
19. Iron (III) isomaltoside 1000.
Mace TA; Syed A; Bhandari S
Expert Rev Hematol; 2013 Jun; 6(3):239-46. PubMed ID: 23782077
[TBL] [Abstract][Full Text] [Related]
20. Intravenous ferric carboxymaltose versus standard medical care in the treatment of iron deficiency anemia in patients with chronic kidney disease: a randomized, active-controlled, multi-center study.
Charytan C; Bernardo MV; Koch TA; Butcher A; Morris D; Bregman DB
Nephrol Dial Transplant; 2013 Apr; 28(4):953-64. PubMed ID: 23222534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
